NASDAQ · NVCT
Nuvectis Pharma, Inc.
$18.57+$0.21 (+1.14%)
Nuvectis Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.58% below the high.
Loading market information…
NASDAQ · IPHA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Innate Pharma S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | Sep 14, 2023 | $0.02-75.15% vs estimate | $42.87M-37.46% vs estimate |
|---|
| Q4 2022 | Mar 23, 2023 | -$0.88-117.19% vs estimate | $13.18M-26.98% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $7.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$18.57+$0.21 (+1.14%)
Nuvectis Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.58% below the high.
CA$15.01-CA$0.21 (-1.38%)
Cybin Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.42% below the high.
$2.04+$0.03 (+1.49%)
Compugen Ltd.’s quoted price sits in the lower half of its reported 52-week range, 37.04% below the high.
$3.53-$0.18 (-4.88%)
Molecular Partners AG’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
$0.79+$0.03 (+4.25%)
Milestone Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.2% below the high.
$4.22-$0.03 (-0.71%)
Corbus Pharmaceuticals Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.52% below the high.
$0.91+$0.01 (+1.6%)
Cardiff Oncology, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.45% below the high.
$0.61-$0.01 (-1.61%)
Rani Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.98% below the high.
